p53 suppresses mutagenic RAD52 and POLθ pathways by orchestrating DNA replication restart homeostasis

  1. Sunetra Roy
  2. Karl-Heinz Tomaszowski
  3. Jessica W Luzwick
  4. Soyoung Park
  5. Jun Li
  6. Maureen Murphy
  7. Katharina Schlacher  Is a corresponding author
  1. UT MD Anderson Cancer Center, United States
  2. The Wistar Institute, United States

Abstract

Classically, p53 tumor suppressor acts in transcription, apoptosis, and cell cycle arrest. Yet, replication-mediated genomic instability is integral to oncogenesis, and p53 mutations promote tumor progression and drug-resistance. By delineating human and murine separation-of-function p53 alleles, we find that p53 null and gain-of-function (GOF) mutations exhibit defects in restart of stalled or damaged DNA replication forks driving genomic instability genetically separable from transcription activation. By assaying protein-DNA fork interactions in single cells, we unveil a p53-MLL3-enabled recruitment of MRE11 DNA replication restart nuclease. Importantly, p53 defects or depletion unexpectedly allow mutagenic RAD52 and POLq pathways to hijack stalled forks, which we find reflected in p53 defective breast-cancer patient COSMIC mutational signatures. These data uncover p53 as a keystone regulator of replication homeostasis within a DNA restart network. Mechanistically, this has important implications for development of resistance in cancer therapy. Combined, these results define an unexpected role for p53-mediated suppression of replication genome instability.

Data availability

The following previously published data sets were used
    1. The Cancer Genome Atlas Research Network
    (2016) Breast Cancer TCGA dataset (TCGA-BRCA)
    Publicly available from the NCI GDC Data Portal (https://cancergenome.nih.gov).

Article and author information

Author details

  1. Sunetra Roy

    Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United States
    Competing interests
    No competing interests declared.
  2. Karl-Heinz Tomaszowski

    Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United States
    Competing interests
    No competing interests declared.
  3. Jessica W Luzwick

    Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United States
    Competing interests
    No competing interests declared.
  4. Soyoung Park

    Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United States
    Competing interests
    No competing interests declared.
  5. Jun Li

    Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, United States
    Competing interests
    No competing interests declared.
  6. Maureen Murphy

    Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, United States
    Competing interests
    Maureen Murphy, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7644-7296
  7. Katharina Schlacher

    Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United States
    For correspondence
    KSchlacher@mdanderson.org
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7226-6391

Funding

Cancer Prevention and Research Institute of Texas (R1312)

  • Katharina Schlacher

National Cancer Institute (K22CA175262)

  • Katharina Schlacher

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2018, Roy et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,263
    views
  • 917
    downloads
  • 70
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sunetra Roy
  2. Karl-Heinz Tomaszowski
  3. Jessica W Luzwick
  4. Soyoung Park
  5. Jun Li
  6. Maureen Murphy
  7. Katharina Schlacher
(2018)
p53 suppresses mutagenic RAD52 and POLθ pathways by orchestrating DNA replication restart homeostasis
eLife 7:e31723.
https://doi.org/10.7554/eLife.31723

Share this article

https://doi.org/10.7554/eLife.31723

Further reading

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.

    1. Cell Biology
    2. Chromosomes and Gene Expression
    Bethany M Bartlett, Yatendra Kumar ... Wendy A Bickmore
    Research Article Updated

    During oncogene-induced senescence there are striking changes in the organisation of heterochromatin in the nucleus. This is accompanied by activation of a pro-inflammatory gene expression programme – the senescence-associated secretory phenotype (SASP) – driven by transcription factors such as NF-κB. The relationship between heterochromatin re-organisation and the SASP has been unclear. Here, we show that TPR, a protein of the nuclear pore complex basket required for heterochromatin re-organisation during senescence, is also required for the very early activation of NF-κB signalling during the stress-response phase of oncogene-induced senescence. This is prior to activation of the SASP and occurs without affecting NF-κB nuclear import. We show that TPR is required for the activation of innate immune signalling at these early stages of senescence and we link this to the formation of heterochromatin-enriched cytoplasmic chromatin fragments thought to bleb off from the nuclear periphery. We show that HMGA1 is also required for cytoplasmic chromatin fragment formation. Together these data suggest that re-organisation of heterochromatin is involved in altered structural integrity of the nuclear periphery during senescence, and that this can lead to activation of cytoplasmic nucleic acid sensing, NF-κB signalling, and activation of the SASP.